Cargando…

Safety and Efficacy of Treatment with/without Ramucirumab in Advanced or Metastatic Cancer: A Meta-Analysis of 11 Global, Double-Blind, Phase 3 Randomized Controlled Trials

Ramucirumab, as a vascular endothelial growth factor receptor-2 inhibitor, was first approved in 2014 for treated advanced or metastatic gastric/gastroesophageal junction (GEJ) adenocarcinoma. This study deeply analyzed the efficacy and safety of advanced or metastatic cancer treated with ramuciruma...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Lingxue, Wang, Tong, Zhang, Qianqian, Yu, Sheng, Li, Wen, Yao, Senbang, Cheng, Huaidong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9705087/
https://www.ncbi.nlm.nih.gov/pubmed/36451771
http://dx.doi.org/10.1155/2022/2476469
_version_ 1784840198059720704
author Tang, Lingxue
Wang, Tong
Zhang, Qianqian
Yu, Sheng
Li, Wen
Yao, Senbang
Cheng, Huaidong
author_facet Tang, Lingxue
Wang, Tong
Zhang, Qianqian
Yu, Sheng
Li, Wen
Yao, Senbang
Cheng, Huaidong
author_sort Tang, Lingxue
collection PubMed
description Ramucirumab, as a vascular endothelial growth factor receptor-2 inhibitor, was first approved in 2014 for treated advanced or metastatic gastric/gastroesophageal junction (GEJ) adenocarcinoma. This study deeply analyzed the efficacy and safety of advanced or metastatic cancer treated with ramucirumab, which included 11 global, double-blind, phase 3 randomized controlled trials with a total of 7410 patients. Subgroup analysis based on different cancer types showed that standard regimens plus ramucirumab significantly increased progression-free survival and overall survival compared with placebo groups in patients with advanced non-small-cell lung cancer (NSCLC), hepatocellular carcinoma, gastric cancer, or GEJ adenocarcinoma. Although a higher proportion of patients achieved overall response and disease control than those treated with placebo, the overall response was not statistically significant between the two groups in advanced NSCLC. Grade 3 or worse treatment-emergent adverse events (TEAEs) that occurred in at least 5% of patients were neutropenia (30.5% in the ramucirumab group vs. 23.5% in the placebo group), leucopenia (14.8% vs. 9.2%), weight decreased (14.2% vs. 8.0%), myalgia (11.7% vs. 7.7%), fatigue (10.9% vs. 7.7%), hypertension (9.2% vs. 2.3%), and anaemia (6.2% vs. 7.7%). In the TEAEs of special interest, the ramucirumab group had a significantly higher incidence of bleeding (mainly grade 1-2 epistaxis and gastrointestinal bleeding), hypertension, proteinuria, liver injury/failure (grade 1-2), venous thromboembolism (grade 1-2), and gastrointestinal perforation (grade ≧3) than the control group.
format Online
Article
Text
id pubmed-9705087
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-97050872022-11-29 Safety and Efficacy of Treatment with/without Ramucirumab in Advanced or Metastatic Cancer: A Meta-Analysis of 11 Global, Double-Blind, Phase 3 Randomized Controlled Trials Tang, Lingxue Wang, Tong Zhang, Qianqian Yu, Sheng Li, Wen Yao, Senbang Cheng, Huaidong J Oncol Review Article Ramucirumab, as a vascular endothelial growth factor receptor-2 inhibitor, was first approved in 2014 for treated advanced or metastatic gastric/gastroesophageal junction (GEJ) adenocarcinoma. This study deeply analyzed the efficacy and safety of advanced or metastatic cancer treated with ramucirumab, which included 11 global, double-blind, phase 3 randomized controlled trials with a total of 7410 patients. Subgroup analysis based on different cancer types showed that standard regimens plus ramucirumab significantly increased progression-free survival and overall survival compared with placebo groups in patients with advanced non-small-cell lung cancer (NSCLC), hepatocellular carcinoma, gastric cancer, or GEJ adenocarcinoma. Although a higher proportion of patients achieved overall response and disease control than those treated with placebo, the overall response was not statistically significant between the two groups in advanced NSCLC. Grade 3 or worse treatment-emergent adverse events (TEAEs) that occurred in at least 5% of patients were neutropenia (30.5% in the ramucirumab group vs. 23.5% in the placebo group), leucopenia (14.8% vs. 9.2%), weight decreased (14.2% vs. 8.0%), myalgia (11.7% vs. 7.7%), fatigue (10.9% vs. 7.7%), hypertension (9.2% vs. 2.3%), and anaemia (6.2% vs. 7.7%). In the TEAEs of special interest, the ramucirumab group had a significantly higher incidence of bleeding (mainly grade 1-2 epistaxis and gastrointestinal bleeding), hypertension, proteinuria, liver injury/failure (grade 1-2), venous thromboembolism (grade 1-2), and gastrointestinal perforation (grade ≧3) than the control group. Hindawi 2022-11-21 /pmc/articles/PMC9705087/ /pubmed/36451771 http://dx.doi.org/10.1155/2022/2476469 Text en Copyright © 2022 Lingxue Tang et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Tang, Lingxue
Wang, Tong
Zhang, Qianqian
Yu, Sheng
Li, Wen
Yao, Senbang
Cheng, Huaidong
Safety and Efficacy of Treatment with/without Ramucirumab in Advanced or Metastatic Cancer: A Meta-Analysis of 11 Global, Double-Blind, Phase 3 Randomized Controlled Trials
title Safety and Efficacy of Treatment with/without Ramucirumab in Advanced or Metastatic Cancer: A Meta-Analysis of 11 Global, Double-Blind, Phase 3 Randomized Controlled Trials
title_full Safety and Efficacy of Treatment with/without Ramucirumab in Advanced or Metastatic Cancer: A Meta-Analysis of 11 Global, Double-Blind, Phase 3 Randomized Controlled Trials
title_fullStr Safety and Efficacy of Treatment with/without Ramucirumab in Advanced or Metastatic Cancer: A Meta-Analysis of 11 Global, Double-Blind, Phase 3 Randomized Controlled Trials
title_full_unstemmed Safety and Efficacy of Treatment with/without Ramucirumab in Advanced or Metastatic Cancer: A Meta-Analysis of 11 Global, Double-Blind, Phase 3 Randomized Controlled Trials
title_short Safety and Efficacy of Treatment with/without Ramucirumab in Advanced or Metastatic Cancer: A Meta-Analysis of 11 Global, Double-Blind, Phase 3 Randomized Controlled Trials
title_sort safety and efficacy of treatment with/without ramucirumab in advanced or metastatic cancer: a meta-analysis of 11 global, double-blind, phase 3 randomized controlled trials
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9705087/
https://www.ncbi.nlm.nih.gov/pubmed/36451771
http://dx.doi.org/10.1155/2022/2476469
work_keys_str_mv AT tanglingxue safetyandefficacyoftreatmentwithwithoutramucirumabinadvancedormetastaticcancerametaanalysisof11globaldoubleblindphase3randomizedcontrolledtrials
AT wangtong safetyandefficacyoftreatmentwithwithoutramucirumabinadvancedormetastaticcancerametaanalysisof11globaldoubleblindphase3randomizedcontrolledtrials
AT zhangqianqian safetyandefficacyoftreatmentwithwithoutramucirumabinadvancedormetastaticcancerametaanalysisof11globaldoubleblindphase3randomizedcontrolledtrials
AT yusheng safetyandefficacyoftreatmentwithwithoutramucirumabinadvancedormetastaticcancerametaanalysisof11globaldoubleblindphase3randomizedcontrolledtrials
AT liwen safetyandefficacyoftreatmentwithwithoutramucirumabinadvancedormetastaticcancerametaanalysisof11globaldoubleblindphase3randomizedcontrolledtrials
AT yaosenbang safetyandefficacyoftreatmentwithwithoutramucirumabinadvancedormetastaticcancerametaanalysisof11globaldoubleblindphase3randomizedcontrolledtrials
AT chenghuaidong safetyandefficacyoftreatmentwithwithoutramucirumabinadvancedormetastaticcancerametaanalysisof11globaldoubleblindphase3randomizedcontrolledtrials